Articles - 3tnh mentioned but not cited (5)
- Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities. Shawky AM, Ibrahim NA, Abourehab MAS, Abdalla AN, Gouda AM. J Enzyme Inhib Med Chem 36 15-33 (2021)
- 2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors. Nkizinkiko Y, Desantis J, Koivunen J, Haikarainen T, Murthy S, Sancineto L, Massari S, Ianni F, Obaji E, Loza MI, Pihlajaniemi T, Brea J, Tabarrini O, Lehtiö L. Sci Rep 8 1680 (2018)
- Ensemble-based modeling and rigidity decomposition of allosteric interaction networks and communication pathways in cyclin-dependent kinases: Differentiating kinase clients of the Hsp90-Cdc37 chaperone. Stetz G, Tse A, Verkhivker GM. PLoS One 12 e0186089 (2017)
- Determining the Functions of HIV-1 Tat and a Second Magnesium Ion in the CDK9/Cyclin T1 Complex: A Molecular Dynamics Simulation Study. Jin HX, Go ML, Yin P, Qiu XT, Zhu P, Yan XJ. PLoS One 10 e0124673 (2015)
- 3,4,3'-Tri-O-methylellagic acid as an anticancer agent: in vitro and in silico studies. Wardana AP, Abdjan MI, Aminah NS, Fahmi MZ, Siswanto I, Kristanti AN, Saputra MA, Takaya Y. RSC Adv 12 29884-29891 (2022)
Reviews citing this publication (5)
- αC helix displacement as a general approach for allosteric modulation of protein kinases. Palmieri L, Rastelli G. Drug Discov Today 18 407-414 (2013)
- CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents. Anshabo AT, Milne R, Wang S, Albrecht H. Front Oncol 11 678559 (2021)
- Recent advances in CDK inhibitors for cancer therapy. Heptinstall AB, Adiyasa I, Cano C, Hardcastle IR. Future Med Chem 10 1369-1388 (2018)
- Structure-based discovery of cyclin-dependent protein kinase inhibitors. Martin MP, Endicott JA, Noble MEM. Essays Biochem 61 439-452 (2017)
- CDK9 inhibitors in cancer research. Huang Z, Wang T, Wang C, Fan Y. RSC Med Chem 13 688-710 (2022)
Articles citing this publication (14)
- Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. Sonawane YA, Taylor MA, Napoleon JV, Rana S, Contreras JI, Natarajan A. J Med Chem 59 8667-8684 (2016)
- Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. Shao H, Shi S, Huang S, Hole AJ, Abbas AY, Baumli S, Liu X, Lam F, Foley DW, Fischer PM, Noble M, Endicott JA, Pepper C, Wang S. J Med Chem 56 640-659 (2013)
- Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers. Sengupta S, Biarnes MC, Jordan VC. Breast Cancer Res Treat 143 113-124 (2014)
- Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity. Hole AJ, Baumli S, Shao H, Shi S, Huang S, Pepper C, Fischer PM, Wang S, Endicott JA, Noble ME. J Med Chem 56 660-670 (2013)
- The CDK9 tail determines the reaction pathway of positive transcription elongation factor b. Baumli S, Hole AJ, Wang LZ, Noble ME, Endicott JA. Structure 20 1788-1795 (2012)
- Computer-aided design, synthesis and validation of 2-phenylquinazolinone fragments as CDK9 inhibitors with anti-HIV-1 Tat-mediated transcription activity. Sancineto L, Iraci N, Massari S, Attanasio V, Corazza G, Barreca ML, Sabatini S, Manfroni G, Avanzi NR, Cecchetti V, Pannecouque C, Marcello A, Tabarrini O. ChemMedChem 8 1941-1953 (2013)
- Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Tong Z, Chatterjee D, Deng D, Veeranki O, Mejia A, Ajani JA, Hofstetter W, Lin S, Guha S, Kopetz S, Krishnan S, Maru D. Oncotarget 8 28696-28710 (2017)
- Computational study and peptide inhibitors design for the CDK9 - cyclin T1 complex. Randjelović J, Erić S, Savić V. J Mol Model 19 1711-1725 (2013)
- Molecular principle of the cyclin-dependent kinase selectivity of 4-(thiazol-5-yl)-2-(phenylamino) pyrimidine-5-carbonitrile derivatives revealed by molecular modeling studies. Kong X, Sun H, Pan P, Tian S, Li D, Li Y, Hou T. Phys Chem Chem Phys 18 2034-2046 (2016)
- Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation. Jorda R, Navrátilová J, Hušková Z, Schütznerová E, Cankař P, Strnad M, Kryštof V. Chem Biol Drug Des 84 402-408 (2014)
- Novel pyrrolizines bearing 3,4,5-trimethoxyphenyl moiety: design, synthesis, molecular docking, and biological evaluation as potential multi-target cytotoxic agents. Shawky AM, Ibrahim NA, Abdalla AN, Abourehab MAS, Gouda AM. J Enzyme Inhib Med Chem 36 1313-1333 (2021)
- Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones. Grigoroudis AI, McInnes C, Premnath PN, Kontopidis G. Protein Expr Purif 113 8-16 (2015)
- Novel arylazopyrazole inhibitors of cyclin-dependent kinases. Jorda R, Schütznerová E, Cankař P, Brychtová V, Navrátilová J, Kryštof V. Bioorg Med Chem 23 1975-1981 (2015)
- Discovery of novel 5-fluoro-N2,N4-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9. Gao J, Fang C, Xiao Z, Huang L, Chen CH, Wang LT, Lee KH. Medchemcomm 6 444-454 (2015)